Company Description
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.
The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases.
It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.
The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief.
In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.
The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020.
Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Eric Weisblum |
Contact Details
Address: 677 N. Washington Boulevard Sarasota, Florida 34236 United States | |
| Phone | 718 400 9031 |
| Website | silopharma.com |
Stock Details
| Ticker Symbol | SILO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001514183 |
| CUSIP Number | 82711P102 |
| ISIN Number | US82711P2011 |
| Employer ID | 46-2137136 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric Weisblum | Chairman, President and Chief Executive Officer |
| Daniel E. Ryweck | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | DEFR14A | Filing |
| Nov 13, 2024 | SCHEDULE 13G | Filing |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 8, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 8, 2024 | 8-K | Current Report |
| Sep 18, 2024 | ARS | Filing |
| Sep 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 18, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 10, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 424B3 | Prospectus |